Figure 1A. TEG graph with parameters

During validation each laboratory must establish their own reference intervals

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Clot time</th>
<th>Clot rate</th>
<th>Maximum clot strength</th>
<th>Clot stability</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemostatic Activity</td>
<td>Thrombin-generation</td>
<td>Fibrin X-linking</td>
<td>Platelet–fibrin(ogen) interactions</td>
<td>Reduction in clot strength</td>
</tr>
<tr>
<td>Hemostatic Component</td>
<td>Coagulation pathways</td>
<td>Coag pathways platelets</td>
<td>Platelets (~40%) Fibrinogen (~20%)</td>
<td>Fibrinolysis</td>
</tr>
</tbody>
</table>

Figure 1B. ROTEM graph with parameters

During validation each laboratory must establish their own reference intervals

CT: Clotting time
CFT: Clot formation time
A(x): Amplitude x mins after CT
MCF: Maximum clot firmness
LI30: Lysis index 30 mins after CT
ML: Maximum lysis
Figure 1C. TEG 5000 characteristic tracing showing hypercoagulable state with low normal R parameter, elevated angle, MA /G and minimal fibrinolysis.